FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8151人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839730, encodeId=8c7c1839e3035, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=无需吃药！FDA批准**精神分裂症皮肤给药疗法, objectType=article, longId=181361, objectId=fe2118136104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2118136104, replyNumber=0, likeNumber=60, createdTime=2019-12-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2118136104, moduleTitle=无需吃药！FDA批准**精神分裂症皮肤给药疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe2118136104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839687, encodeId=0c53183968e9b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准GATTEX用于治疗短肠综合症（SBS）儿童患者, objectType=article, longId=166326, objectId=480a16632698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=480a16632698, replyNumber=0, likeNumber=68, createdTime=2019-09-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=480a16632698, moduleTitle=美国FDA批准GATTEX用于治疗短肠综合症（SBS）儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=480a16632698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839756, encodeId=03261839e5656, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗, objectType=article, longId=184954, objectId=668a18495452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=668a18495452, replyNumber=0, likeNumber=73, createdTime=2020-01-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=668a18495452, moduleTitle=阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=668a18495452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839710, encodeId=c4e91839e108c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=81, createdTime=2019-10-22, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839698, encodeId=8720183969864, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, objectType=article, longId=174342, objectId=3d2b1e4342ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d2b1e4342ca, replyNumber=0, likeNumber=0, createdTime=2020-01-25, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d2b1e4342ca, moduleTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d2b1e4342ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839671, encodeId=729d18396e118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准针对三阴性乳腺癌的免疫治疗方案, objectType=article, longId=162541, objectId=6ac0162541c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ac0162541c2, replyNumber=0, likeNumber=81, createdTime=2019-05-04, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ac0162541c2, moduleTitle=FDA批准针对三阴性乳腺癌的免疫治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ac0162541c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839754, encodeId=eb951839e5434, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, objectType=article, longId=184900, objectId=b47618490022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b47618490022, replyNumber=0, likeNumber=62, createdTime=2020-02-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b47618490022, moduleTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b47618490022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839667, encodeId=88f2183966e7e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国早期血管内出血监测设备Early Bird获FDA批准, objectType=article, longId=161926, objectId=cdfe16192644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdfe16192644, replyNumber=0, likeNumber=60, createdTime=2019-11-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdfe16192644, moduleTitle=美国早期血管内出血监测设备Early Bird获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdfe16192644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839731, encodeId=0f501839e3180, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=**款针对高风险流感并发症药物Xofluza，喜获FDA批准, objectType=article, longId=181601, objectId=cbbc181601d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbbc181601d4, replyNumber=0, likeNumber=54, createdTime=2020-07-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbbc181601d4, moduleTitle=**款针对高风险流感并发症药物Xofluza，喜获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbbc181601d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839745, encodeId=0a551839e459a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准：间充质干细胞治疗阿尔茨海默症的突破性临床试验, objectType=article, longId=183350, objectId=73a4183350de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73a4183350de, replyNumber=0, likeNumber=64, createdTime=2020-02-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73a4183350de, moduleTitle=FDA批准：间充质干细胞治疗阿尔茨海默症的突破性临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73a4183350de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839744, encodeId=9b5e1839e44d9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=诺华的Adakveo获得FDA批准治疗镰状细胞性疼痛, objectType=article, longId=183194, objectId=5578183194d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5578183194d4, replyNumber=0, likeNumber=67, createdTime=2019-12-13, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5578183194d4, moduleTitle=诺华的Adakveo获得FDA批准治疗镰状细胞性疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5578183194d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839657, encodeId=43d5183965e9e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=从FDA批准的PD-(L)1类药物适应症看中国肿瘤免疫药物开发进展, objectType=article, longId=161087, objectId=39d816108ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d816108ef7, replyNumber=0, likeNumber=60, createdTime=2019-03-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d816108ef7, moduleTitle=从FDA批准的PD-(L)1类药物适应症看中国肿瘤免疫药物开发进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d816108ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839738, encodeId=e75e1839e386b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=RedHill Biopharma宣布FDA批准Talicia用于治疗成人幽门螺旋杆菌感染, objectType=article, longId=182393, objectId=3c1f1823939d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c1f1823939d, replyNumber=0, likeNumber=58, createdTime=2020-02-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c1f1823939d, moduleTitle=RedHill Biopharma宣布FDA批准Talicia用于治疗成人幽门螺旋杆菌感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c1f1823939d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839660, encodeId=98eb1839660f0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Heron的补充新药申请以扩大CINVANTI的标签, objectType=article, longId=161339, objectId=bce91613398a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce91613398a, replyNumber=0, likeNumber=52, createdTime=2020-01-07, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce91613398a, moduleTitle=FDA批准Heron的补充新药申请以扩大CINVANTI的标签, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce91613398a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839647, encodeId=3b6e183964e4b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准UniQure开展亨廷顿病的AAV基因治疗临床试验, objectType=article, longId=158975, objectId=56e61589e539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56e61589e539, replyNumber=0, likeNumber=51, createdTime=2019-09-21, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56e61589e539, moduleTitle=FDA批准UniQure开展亨廷顿病的AAV基因治疗临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56e61589e539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839734, encodeId=01bf1839e3489, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, objectType=article, longId=181708, objectId=3487181e0866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3487181e0866, replyNumber=0, likeNumber=13, createdTime=2020-05-16, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3487181e0866, moduleTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3487181e0866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839706, encodeId=1c201839e06f0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Turalio（pexidartinib）治疗腱鞘巨细胞瘤, objectType=article, longId=176829, objectId=02d81e6829c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d81e6829c1, replyNumber=0, likeNumber=80, createdTime=2020-01-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d81e6829c1, moduleTitle=FDA批准Turalio（pexidartinib）治疗腱鞘巨细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d81e6829c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839645, encodeId=87fe183964578, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准23andMe结直肠癌检测，包含两个相关突变, objectType=article, longId=158722, objectId=afa1158e220b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afa1158e220b, replyNumber=0, likeNumber=51, createdTime=2019-11-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa1158e220b, moduleTitle=FDA批准23andMe结直肠癌检测，包含两个相关突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afa1158e220b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839637, encodeId=1ea9183963e85, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了Intellipharmaceutics的文拉法辛盐酸缓释胶囊, objectType=article, longId=154592, objectId=88751545921e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88751545921e, replyNumber=0, likeNumber=63, createdTime=2019-08-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88751545921e, moduleTitle=FDA批准了Intellipharmaceutics的文拉法辛盐酸缓释胶囊, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88751545921e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839705, encodeId=5c111839e0568, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=**肿瘤学数字疗法获FDA批准，可针对所有癌症适应症, objectType=article, longId=176740, objectId=0a581e674060, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a581e674060, replyNumber=0, likeNumber=108, createdTime=2020-03-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a581e674060, moduleTitle=**肿瘤学数字疗法获FDA批准，可针对所有癌症适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a581e674060)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

无需吃药！FDA批准**精神分裂症皮肤给药疗法

2019-12-17

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准GATTEX用于治疗短肠综合症（SBS）儿童患者

2019-09-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗

2020-01-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC

2019-10-22

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症

2020-01-25

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准针对三阴性乳腺癌的免疫治疗方案

2019-05-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌

2020-02-17

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

美国早期血管内出血监测设备Early Bird获FDA批准

2019-11-28

bugit (审核中...)

前往app查看评论内容

#FDA批准#

**款针对高风险流感并发症药物Xofluza，喜获FDA批准

2020-07-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准：间充质干细胞治疗阿尔茨海默症的突破性临床试验

2020-02-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

诺华的Adakveo获得FDA批准治疗镰状细胞性疼痛

2019-12-13

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

从FDA批准的PD-(L)1类药物适应症看中国肿瘤免疫药物开发进展

2019-03-22

bugit (审核中...)

前往app查看评论内容

#FDA批准#

RedHill Biopharma宣布FDA批准Talicia用于治疗成人幽门螺旋杆菌感染

2020-02-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Heron的补充新药申请以扩大CINVANTI的标签

2020-01-07

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准UniQure开展亨廷顿病的AAV基因治疗临床试验

2019-09-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

2020-05-16

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Turalio（pexidartinib）治疗腱鞘巨细胞瘤

2020-01-03

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准23andMe结直肠癌检测，包含两个相关突变

2019-11-29

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了Intellipharmaceutics的文拉法辛盐酸缓释胶囊

2019-08-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

**肿瘤学数字疗法获FDA批准，可针对所有癌症适应症

2020-03-17

科室
- - 订阅+
  - 更多科室
工具
服务